<DOC>
	<DOCNO>NCT01836523</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial confirm efficacy safety liraglutide adjunct therapy insulin treatment type 1 diabetes . The total trial duration per subject approximately 58 week .</brief_summary>
	<brief_title>The Efficacy Safety Liraglutide Adjunct Therapy Insulin Treatment Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain Type 1 diabetes mellitus 12 month long Basal bolus CSII ( Continuous Subcutaneous Insulin Infusion , insulin pump ) treatment 6 month longer Stable insulin treatment last 3 month prior Screening , judge document investigator HbA1c 7.010 % ( Diabetes Control Complications Trial ( DCCT ) ) , inclusive , ( correspond 5386 mmol/mol ( International Federation Clinical Chemistry ( IFCC ) ) Ability willingness comply protocol procedure e.g . correct handle trial product , complete trial related questionnaire , diary , selfmonitoring plasma glucose , self titration insulin attend schedule visit Prior use glucagonlike peptide1 ( GLP1 ) receptor agonist dipeptidyl peptidase IV ( DPP4 ) inhibitor Use medication , investigator 's opinion could interfere glycaemic control affect subject 's safety.Premix insulin allow Known proliferative retinopathy maculopathy require acute treatment Severe neuropathy , particular autonomic neuropathy , i.e . gastroparesis , judge investigator Uncontrolled/ untreated blood pressure screen 160 mmHg systolic 100 mmHg diastolic History acute chronic pancreatitis Screening calcitonin value equal 50 ng/L Personal family history medullary thyroid carcinoma Multiple Endocrine Neoplasia type 2 ( MEN2 ) Diagnosis malignant neoplasm previous 5 year ( except basal cell skin cancer squamous cell skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>